| Market Capitalization (Millions $) |
278 |
| Shares
Outstanding (Millions) |
1,642 |
| Employees |
105 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
-39 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Bethesda, Maryland, that specializes in developing personalized immunotherapy products for the treatment of cancer. The company's focus is on developing and commercializing novel cancer therapies based on its DCVax platform technology, which involves using dendritic cells to stimulate the body's immune system to fight cancer.
DCVax is a unique personalized immunotherapy platform that involves extracting dendritic cells from a patient's blood and then exposing them to tumor antigens in order to activate the immune system's T-cells to attack the cancer. The activated dendritic cells are then injected back into the patient to stimulate an immune response against the cancer.
The company has several clinical trials underway for its DCVax products, including:
- DCVax-L for glioblastoma multiforme (GBM), a deadly form of brain cancer that has limited treatment options. The Phase III trial for this product has completed enrollment and awaits data analysis.
- DCVax-Direct for all solid tumor cancers, which involves injecting activated dendritic cells directly into tumors. This product is currently in Phase I/II trials.
- DCVax-Prostate for prostate cancer, which is in Phase II trials.
Northwest Biotherapeutics has also developed a specialized manufacturing facility for the production of its personalized immunotherapy products, which has received approval from the U.S. Food and Drug Administration (FDA). The company's manufacturing process is designed to ensure consistency and quality in the production of its DCVax products.
In addition to its DCVax products, Northwest Biotherapeutics is also developing other cancer therapies, including:
- Allo-528, a monoclonal antibody for the treatment of acute leukemia and other hematologic malignancies. This product is currently in preclinical development.
- DCVax-L-NG for pediatric brain cancer, which is also currently in preclinical development.
Northwest Biotherapeutics has received several grants and awards for its innovative cancer research and development, including from the National Cancer Institute and the European Union. The company has also received funding from investors, including institutional investors, to support its clinical trials and operations.
In summary, Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized cancer immunotherapy products using its DCVax platform technology. The company has several clinical trials underway for its DCVax products and has also developed a specialized manufacturing facility for their production. In addition, Northwest Biotherapeutics is developing other cancer therapies, and has received grants and funding to support its research and development efforts.
Company Address: 4800 Montgomery Lane Bethesda 20814 MD
Company Phone Number: 497-9024 Stock Exchange / Ticker: NONE NWBO
|
2.47%